Novartis’ medicine Vijoice® (alpelisib) has recently (6 April) been approved by the US Food and Drug Administration (FDA) for the treatment of patients aged two years and older with severe manifestations of PIK3CA-related overgrowth syndrome (PROS). Until today, the only treatment options for these patients are surgical or interventional radiology procedures.
